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There is evidence suggesting that autoimmune mechanisms may influence fertility, manifest-
ing as infertility or pregnancy loss. Numerous autoimmune diseases, including but not lim-
ited to systemic lupus erythematosus, anti-phospholipid syndrome and Hashimoto thyroiditis 
may be associated with infertility and pregnancy loss through different putative mechanisms. 
It is notable that fertility may be impaired in the presence of serum autoantibodies regardless 
of the presence of a clinically overt autoimmune disease. Autoimmunity may affect all stages 
of fertility via ovarian failure, implantation failure, and pregnancy loss. This review article will 
illustrate and discuss the available data on the link between chances of achieving pregnancy 
through Assisted Reproductive Technologies in real clinical setting in the presence of several 
autoantibodies affecting female reproductive system. Summarizing the available data from the 
world literature, it can be concluded that necessity exist in development of a reproductively 
significant antibodies line in application to direct, cross-over and cumulative assessment of 
the role of autoimmune antibodies carriage in the implementation of reproductive failures, 
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bearing in mind new approaches to the strategy of overcoming autoimmune reproductive 
failure. 
Keywords: autoantibodies, TPO, APA, ANA, α-enolase, laminin-1, Se-binding protein 1.
Introduction
Prevalence of barrenness within marriage remains at stably high level (8–15 %), 
despite of the active introduction and availability of assisted reproductive technologies 
(ART) [1–4].
According to European Society of Human Reproduction and Embryology (ESHRE), 
the cause of barrenness remains unknown in 10–20 % cases [5]. Infertility and unfa-
vorable results of In vitro fertilization (IVF) using Intra cytoplasmic sperm injection 
(ICSI) in case of autoimmune diseases is the object of deliberate attention and increases 
interest of many investigators [6–10]. Notable the fact that in women diagnosed with 
idiopathic infertility increased level of serum antiphospholipid antibodies, antinuclear 
antibodies and antibodies to thyroid gland tissue are often detected [9; 11–17]. Auto-
immune disorders are also widely discussed last years and are considered etiological 
factors in implantation failure development [8; 18–28]. Besides, according to reports of 
some investigators, presence of circulating serum antibodies may result in development 
of premature ovarian insufficiency [3; 19; 29–34]. The role of cellular immunity in re-
peated implantation failures in course of IVF/ICSI programs in patients with infertility 
and autoimmune diseases is studied [35; 36]. From the above-listed it becomes obvious 
that there is an existence of various autoimmune mechanisms impacting the female 
reproductive potential.
Thereby, the purpose of this survey article is to study evidence based on available 
world literature concerning the influence of different antibodies on female fertility with 
the aim to perform comprehensive analysis of possible associations between antibodies 
carrier state and successfulness of infertility treatment using assisted reproductive tech-
nologies (ART). The analysis concerns the most prevailing antibodies, about the influence 
of which on reproductive system was reported earlier including antithyroid, antiphospho-
lipid, antinuclear antibodies, as well as less known antibodies to laminin-1, α-enolase-1, 
beta-hCG, aromatase, Se-binding protein-1 (SBP-1) and to mesothelin.
Anti-thyroid antibodies
It is known, that Graves’ disease (GD), occurring with thyrotoxicosis, and autoim-
mune thyroiditis (AIT), being the main cause of hypothyroidism, may alter the function 
of female reproductive system causing menstrual irregularities, infertility and recur-
rent miscarriage [37–39]. In prevailing majority of patients diagnostically significant 
autoantibodies to thyroperoxidase (AT-TPO), thyroglobulin (АT-ТG), and to some 
other colloid and cytoplasmic autoantigenes were detected. It is interesting to note, that 
among women with infertility of unknown origin the prevalence of autoimmune thy-
roiditis constitutes approximately 10 % [9]. It is important to note that antibodies car-
rier state with normal thyroid function among women of reproductive age constitutes 
at average 8–14 % [40] and is often not diagnosed due to the absence of typical clinical 
symptoms of the disease.
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In accessible literature results of possible mechanisms of isolated antibodies to thy-
roperoxidase (AT-TPO) and to thyroglobulin (АT-ТG) carrier state on the state of repro-
ductive system are presented [11–13; 41–42]. 
According to the theory of Monteleone et al. (2011), female infertility associated with 
autoimmune thyroiditis may be caused by the changes in the structures of follicles [11]. 
Presence of АT-ТG and AT-TPO was detected in all samples of female follicular fluid with 
AIT. Moreover, there was clear correlation with the level of serum antibodies indicat-
ing on their ability to pass freely through blood-follicle barrier. To the author’s opinion, 
anti-thyroid antibodies may exert direct toxic effect on the growing follicle and adversely 
affect the quality of future embryo due to the direct interaction with zona pellucida anti-
gens, disordering its functional role. Indeed, in the performed investigation the fertiliza-
tion rate, number of good quality embryos and clinical pregnancy rate were considerably 
lower in the main group when compared with controls. These data enables to propose a 
direct impact of antithyroid antibodies on ovarian tissue. Later, it was reported that after 
the exclusion from investigation of women with a known cause of diminished ovarian 
reserve, the frequency of AT-TPO carrier state considerably differed among women with 
decreased (22.7 %), normal (14.0 %) and high (10.3 %, р = 0.012) ovarian reserve [12].
Data exists that in women — carriers of antithyroid antibodies the quality of embryos, 
obtained in assisted reproductive technology (ART) programs, frequently suffers. So Werg-
hofer et.al. performed case-control study investigating АIТ effect on embryo quality, ob-
tained during intra cytoplasmic sperm injection (ICSI) among women with decreased ovar-
ian reserve [41]. Embryos were described in accordance with Gardner DK criteria (2003). 
Downtrend in embryo quality was detected in women from study group, regardless of thy-
roid stimulating hormone (TSH) level (р = 0.056). Obtained results find a reflection in the 
theory of Monteleone et. al. (2011), and, extremely important, underlines key effect, namely 
of antibodies, but not hypothyroidism, on the results of IVF/ICSI procedures.
A number of authors also performed studies on treatment results using assisted re-
productive technologies [9; 18; 43; 44]. ART outcomes were investigated by Medenica 
et al. [43] among in total of 52 women (26 TAI positive subjects and 26 age and body 
mass index matched TAI negative controls). Twenty patients were on levothyroxine sub-
stitution (mean daily levothyroxine dose was 67.49 ± 29.40 mcg, treatment duration was 
19.50  months). According to obtained results, no statistically significant difference be-
tween the number of oocytes retrieved and fertilization rate in compared groups was re-
vealed. But the implantation rate was considerably lower in the group of patients with AIT 
when compared with control group (21.01 vs to 31.94 %, р = 0.005). 
Similar data were obtained in the retrospective study of Zhong et al. [18] including a 
total of 90 patients (156 cycles) positive for antithyroid antibody and 676 infertile women 
(1062 cycles) negative for antithyroid antibody, undergoing IVF/ICSI. were included. The 
number of oocytes retrieved was comparable between these groups. But fertilization rate 
(64.3 vs 74.6 %, р < 0.001) and implantation rate (17.8 vs 27.1 %, p < 0.001) were signifi-
cantly lower in the group of patients with AIT in comparison to the control group. Never-
theless, the authors did not report on thyroid-stimulating hormone levels before starting 
stimulation. 
However, contrary data also exist. Based on systematic review of nine articles, in-
vestigating the results of IVF/ICSI cycles among 4396 women — carriers of anti-thyroid 
antibodies, Busnelli et al. revealed the absence of difference in the number of oocytes 
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retrieved (p = 0.28), fertilization rate (p = 0.13)  and implantation rate (p = 0.91)  among 
АТ-ТPО carriers within fertility treatment program in respect to control group [44]. The 
authors themselves, using the theory of Monteleone et al. [11], consider that the possible 
reason in the absence of any difference in fertilization and implantation rates between 
the compared groups was the analysis of these indicators only in ICSI protocols, but not 
conventional IVF protocols. On the basis of this assumption they suggested a theory that 
it is possible to bypass negative impact of antithyroid antibodies at zona pellucida by per-
forming ICSI procedure. 
In support to their opinion, Poppe at el. performed meta-analysis of four studies devot-
ed to the results of ICSI procedures among women with subclinical hypothyroidism and TAI 
[9] in comparison to healthy infertile women and did not reveal any differences in fertiliza-
tion rate (р = 0.09) and implantation rate (р = 0.92). Thereby, the theory suggested in 2016 
[44] may appeared rather reasonable, considering the results obtained in 2018 [9]. 
Antiphospholipid antibodies
Antiphospholipid syndrome (APS) represents one of the most prevalent acquired 
trombophilia and causes venous, arterial and microvascular thrombosis and is character-
ized by the antiphospholipid antibodies (aPL) presence, mainly lupus anticoagulant (LA), 
anticardiolipin antibodies (aCL) and antibodies to β2 glycoprotein-I (β-2GPI), directed 
against negatively charged phospholipids [45]. Anti-phospholipid syndrome is associated 
with systemic lupus erythematosus (SLE) in about 35 % cases, lupus-like syndrome is ob-
served in 5  % of patients. Average age of the disease debut constitutes 31 years with ratio 
of female to male patients 5/1 [45; 46]. 
If aPL role in recurrent pregnancy loss is obvious [47–49], its role in infertility and 
IVF failures remains debatable. For the first time hypothesis concerning harmful effects of 
antiphospholipid antibodies on female fertility was suggested in 1980s years [50]. At pre-
sent time there are available data that among 8–9 % of women with infertility of unknown 
origin and multiple IVF failures more than one type of antiphospholipid antibodies are de-
termined when compared with 1.5 % in control group of fertile women (p = 0.0001) [14]. 
According to another sources, aPL are present in 15–59 % of women with idiopathic in-
fertility [15]. After almost a decade Blank et al. in an experimental study demonstrated, 
that in mice earlier non immunized with anticardiolipin antibodies, after injection of im-
munoglobulin IgM & IgG to cardiolipin, a delay in fertilization and in clinical pregnancy 
rate was observed, while the rate of embryo resorption was increased [51]. 
The question of antiphospholipid antibodies influence on the embryo implantation 
and invasion step remains opened and debatable. Impaired angiogenesis in endometrium 
may be responsible for decreased endometrium receptivity and implantation disturbanc-
es. Using experimental models by injecting monoclonal antiphospholipid antibodies to 
naïve mice a direct negative APA effect on embryo development [52; 53] and on endome-
trium was revealed [54]. Sthoeger at el. reported that injection of mice with monoclonal 
antibodies to cardiolipin resulted in implantation failure due to binding APA with tro-
phectoderm cells [53]. Kaider et al. demonstrated a delay in embryo development or even 
death, when cultivated with antiphospholipid antibodies IgG, in comparison to embryos, 
cultivated with control Ig [52]. Tartakovsky et al. reported that embryos obtained from 
mice after injected with monoclonal IgG АPА, lost ability to implantation after their re-
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moval from media with antiphospholipid antibodies and placing them into uterus of the 
mice who did not receive АPА injection [54].
Besides, in some experimental studies using immunohistochemistry analysis, an-
tiphospholipid antibodies of IgG & IgA classes were detected around endometrial glands, 
inside extracellular space of lamina propria and other structures. Levels of IgA 3-4 times 
exceeded the amount of IgG and total levels of immunoglobulin considerably increased 
from 1st to 5th day of pregnancy [55].
It is notable, that among women undergoing IVF, disorders in pre-implantation em-
bryo morphology were detected in 50 % of patients with high serum anti-cardiolipin an-
tibody levels in comparison to 20 % of patients without aCL [56]. It may be explained by 
proven fact of immunoglobulin detection in the follicular fluid, because in a number of 
experimental studies and clinical investigations, performed on patients after IVF, identi-
fication and dynamics of changes in IgG, IgA, IgM concentrations alone with the other 
immunological indicators was carried out. In a study, performed by Matsubayashi, con-
tent of IgG АPА in follicular fluid of patients with multiple IVF failures was studied. In all 
patients positive for antiphospholipid antibodies IgG, immunoglobulins were detected in 
the follicular fluid [57].
Increased interest to АPА influence on pregnancy achieved through assisted repro-
ductive technologies resulted in multiple clinical investigations devoted to relation of АPА 
presence and multiple IVF failures.
In the study of Coulam C. B. the frequency of APA among women with negative 
pregnancy test after IVF treatment and with biochemical pregnancies was studied. As a 
result, the rate of АPА detection in women with bio-chemical pregnancies was reliably 
higher than in nonpregnant women (80 and 28 % respectively; p < 0.0001) [58]. The au-
thors supposed that the reason of pregnancy interruption lays in altered angiogenesis, 
and in concordance to other studies [59; 60] confirms the role of APA in early reproduc-
tive losses.
In a cohort prospective study on APA influence on the results of the first IVF protocol 
among 1720 infertile women, antibodies to cardiolipin IgG (aCL-IgG) were detected in 
11.2 % patients, aCL-IgМ — in 1.3 %, antibodies IgG to β2-glycoprotein (β2GPII) were 
found in 11.7 %, and IgМ-β2GPII in 10.3 % cases. Control group included 844 women 
without antibodies. By the result of embryological protocols, both groups appeared com-
parable in number and quality of oocytes retrieved and the fertilization rate. At the same 
time, lower implantation rate (23.5 vs 42.7 %, р < 0.05) and clinical pregnancy rate (36.4 vs 
61.0 %, р < 0.05) in the group of patients with IgG — β2GPII [3] was noted.
In the study of Kikuchi at el. [16] a reliable decrease of IVF efficiency after the first 
treatment cycle in women with APA was detected. Implantation rate after the first embryo 
transfer constituted 14.8 % as compared with APA-negative women (32.4 %, p < 0.005). 
But cumulative IVF efficiency in both groups turned out to be the same in next protocols. 
The authors concluded that the presence of antiphospholipid antibodies results in de-
creased IVF efficiency only in stimulation protocol, but does not influence the cumulative 
efficiency, and recommend efficient and safe preparations assignment in order to improve 
implantation rate.
Thereby, the role of antiphospholipid antibodies in development of ART program 
failures is not fully determined, but this question is extremely relevant for a wide range of 
researchers and clinicians. 
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Antinuclear antibodies
Represent a group of autoantibodies to proteins and other components, located in 
cell nucleus and are detected in over than 90 % patients with systemic connective tissue 
diseases, such as systemic lupus erythematosus (SLE), systemic sclerosis (SS), Sjögren’s 
Syndrome (SS), mixed connective tissue disease (MCTD), polymyositis/dermatomyosi-
tis (PM/DM). It is necessary to notice, that spectrum of antinuclear antibodies (ANA) 
include a big group of antibodies to dsDNA, nucleoproteins, histones, nuclear RNP and 
other nuclear components.
It is well known that antinuclear antibodies are involved in pathogenesis of a number 
of systemic autoimmune diseases [61–66]. 
The data presented in literature indicate that antinuclear antibodies presence is also 
connected to immunologically induced infertility. Such, investigations demonstrated that 
antinuclear antibodies are seen in 20–28.7 % of infertile women undergoing IVF-ET treat-
ment [16; 17]. Besides that, antinuclear antibodies prevalence constitutes 35.1 % among 
women with recurrent IVF failure [67] and 27 % among women with endometriosis [68]. 
Studies exist revealing connection between ANA presence and repeated IVF failure [20-
23]. Nevertheless, the main mechanisms leading to that are not still completely under-
stood. There is evidence indicating positive correlation between antinuclear antibodies 
levels in the serum and in the follicular fluid. At the same time a negative correlation 
between antibody levels with the number of good quality embryos, obtained in IVF/ICSI 
cycles [69] was noted. 
In addition, experimental studies in vivo were carried out when two cell stage mice 
embryos were co-incubated with purified immunoglobulin IgG. Upon termination, im-
munofluorescence analysis was performed for antinuclear antibodies detection within em-
bryos and revealed clear fluorescent signal directly in embryos. Moreover, some embryos 
exerted a delay in development or even total arrest [70]. However, because zona pellucida 
does not contain nuclear antigens and phospholipids, specific epitope for those antibodies 
remains unknown [71]. In another experimental study a complete arrest of meiosis after 
microinjection of anticentromere antibodies IgG (АСА) to rat oocytes occurred [72]. The 
above-listed enables to suppose that antinuclear antibodies are able to exert direct toxic 
impact on oocyte and embryo development resulting in infertility. 
In available literature the influence of given antibodies on the results of IVF programs 
are presented [3; 20–23; 69; 73–76]. For instance, in 2012 a group of scientists from China 
evaluated embryo quality obtained during infertility treatment in the presence of antinu-
clear antibodies detection. The number of mature ovocytes MII (68.5 vs 82.6 %, р < 0.001), 
2PN (zygotes with two pronuclei) (52.4 vs 58.5 %, р = 0.003) and a number of good quality 
embryos (22.4 vs 31.8 %, р < 0.001) appeared considerably lower in the study group (96 cy-
cles) in comparison to the control group (285 cycles). Moreover, implantation rate (15 vs 
25.7 %) among patients positive for antinuclear antibodies, significantly differed from that 
in the ANA negative group. Thus, the authors concluded that antinuclear antibodies pres-
ence impairs oocyte maturation, embryo and fetal development resulting in decreased 
implantation and pregnancy rate in IVF/ICSI programs [69].
In later study of the same authors a reliable decline of ART programs efficiency in the 
presence of antinuclear antibodies was confirmed again, i. e. less number of high qual-
ity embryos, lower implantation rate and clinical pregnancy rate. Besides the fact that 
262 Вестник СПбГУ. Медицина. 2020. Т. 15. Вып. 4
IgG antibodies were presented in the follicular fluid of seropositive women, they were 
detected within embryos. Important to notice that the mentioned analysis was carried 
out exclusively on embryos of poor quality not subjected to transfer preventing further 
understanding of possible antibody damaging mechanisms on pregnancy onset and de-
velopment potential [73]. 
Antibodies to laminin-1
The influence of antibodies to laminin-1 on female reproductive potential is discussed 
more and more frequently in scientific communities. First described in 1978, laminin pre-
sents a multifunctional adhesive glycoprotein of basal membranes and thin extracellular 
matrix and consists of α-, β-, and γ-chains [77]. It is known, that in early stage human 
embryo cells laminin-1 increases the expression of type IV collagenase enhancing thopho-
blast adhesion during peri-implantation period [78]. In humans during the first trimester 
of pregnancy α-1 chain of laminin is detected in basal membrane of thophoblast and at 
the spots of direct contact with the cells of extravillous trophoblast. In the second preg-
nancy trimester it is present selectively at the places of direct contact between villous basal 
membrane and proliferating islands of trophoblastic cells [79]. Thereby, laminin-1 may 
play important role in all the processes associated with embryo implantation, placentation 
and embryogenesis. 
Antibodies to laminin-1 were firstly extracted in 1989 from primates with reproduc-
tive function failure, and when cultivated with rat embryos developmental delay in the 
latter was detected [80]. In later works, experimental models were created in which high 
titers of antibodies to this antigen were determined in animals after murine laminin-1 in-
jection. The authors noted a tendency towards unsuccessful pregnancy outcomes among 
the tested animals expressed in a higher frequency of fetal resorption, a decrease in the 
weight of the placenta and the weight of embryos for a given gestational age [81].
The role of antibodies to laminin-1 in reproductive failure has also been extensively 
studied in humans. In the early 2000s, in a clinical study by Inagaki et al. found a signifi-
cantly higher incidence of recurrent first trimester miscarriages among women carriers 
of anti-laminin-1 IgG antibodies [24]. A total of 177 women with a history of recurrent 
miscarriage were tested for antibodies against laminin-1, b2-glycoprotein I (b2-GPI), lu-
pus anticoagulant, antibodies to double-stranded DNA and antinuclear antibodies be-
fore the onset of the next pregnancy. Anti-lamini-1 IgG was detected in 55 of 177 women 
(31.1 %) with a history of miscarriage. Anti-laminin-1 IgG titers were significantly higher 
in the test group relative to women with normal pregnancies and healthy non-pregnant 
women (p = 0.0043 and 0.0073, respectively). Subsequently, the frequency of live births 
in the laminin-1 group was significantly lower than in the controls (p = 0.032). Thus, the 
authors suggested that IgG antibodies to laminin-1 exert a direct toxic effect on the earliest 
stages of pregnancy during embryo implantation, embryogenesis, and active angiogenesis 
in the placenta.
In the world literature data also exist highlighting the relationship between antibodies 
to laminin-1 presence with infertility, especially caused by endometriosis (29 % of affected 
women) [82; 83]. The presence of autoantibodies in the study group significantly correlated 
with the presence of endometriosis (p = 0.0096). When comparing the mean values of the 
antibody content in the groups of infertile women with and without endometriosis, higher 
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rates were noted among 42 women with endometriosis (mean value 1.1 ± 1.2 U/ml) com-
pared with the control group (mean value 0.46 ± 0.33 U/ml) (p = 0.015) [82].
It is now also known that laminin-1, along with fibronectin, plays an important role 
in the maturation of oocytes by accelerating the formation of polar bodies [84]. Based 
on this, it can be assumed that antibodies to laminin should also be detected in follicular 
fluid. And, in fact, for the first time, these antibodies were detected in the follicular fluid 
of women with endometriosis (31 % of examined) by Caccavo et al. in 2011 [83] and posi-
tively correlated with serum levels. Based on this fact, the authors suggested that antibod-
ies to laminin-1 are able to freely pass through the blood-follicular barrier. In the same 
study, the authors revealed a peculiarity: the number of mature MII oocytes negatively 
correlated with the level of antibodies in the follicular fluid (p = 0.0006). At the same time, 
the frequency of ongoing pregnancy did not differ significantly among women with or 
without circulating antibodies (36 vs 29 %, p = 0.7), which led to the conclusion that there 
was no negative effect of AT-laminin-1 on the effectiveness of the IVF procedure.
In a later research of the same scientists for the first time the fact of high titers of an-
tibodies to laminin-1 in the sera of women with AIT (19/44 — 43.2 %) compared with the 
control group (1/28 — 3.6 %) was reported. In IVF cycles, a negative correlation was found 
between the number of mature oocytes and the level of AT-laminin-1 in the follicular fluid 
(p = 0.03). However, the incidence of implantation rate and clinical pregnancy rate was 
much lower in the group of patients with AIT (p = 0.015) compared with the control group 
(p = 0.03). Thus, a negative influence of AT-laminin-1 along with AT-TPO on the results 
of IVF cycles was revealed [84].
Antibodies to α-enolase-1
In 2018, a group of German scientists conducted a study to identify antibodies in-
volved in recurrent miscarriage. Using Western blotting and mass spectrometry, the au-
thors discovered a new target for antibodies to trophoblast, namely enolase-1 (ENO1), 
which is detected in the JEG-3 choriocarcinoma cell line as well as in the tissue of extravil-
lous trophoblast of the first trimester of pregnancy [25]. As known, ENO1 is a multifunc-
tional glycolytic enzyme weighing 45–47 kDa and is abundant in the cytoplasm of differ-
ent cells. It has been proven that antibodies to enolase-1 are present in some autoimmune 
diseases, such as rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, 
Behcet’s disease, ulcerative colitis, Crohn’s disease, and primary sclerosing cholangitis 
[85]. The relationship between the carriage of these antibodies with endometriosis and 
premature ovarian failure is also being discussed [86; 87]. Sarapik et al. revealed a higher 
incidence of antibodies to enolase-1 IgA among women with peritoneal infertility [86]. 
According to other opinions, ENO1 represents a specific antigen for anti-endometrial an-
tibodies [87]. The serum values were significantly higher among women with recurrent 
miscarriage when compared with the control group. Thus, there are numerous reports on 
the negative effect of antibodies to enolase-1 on female reproductive health.
It is known that antibodies to enolase-1 are found in large quantities in the decidual 
tissue of the first trimester placenta (about 9 weeks of gestation) among women with a 
history of recurrent miscarriage. Moreover, in vitro, antibodies against ENO1 inhibited 
the production of β-hCG and progesterone by the cells of the human villous trophoblast. 
Thus, the authors suggest that these antibodies may become a new autoimmune biomarker 
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for recurrent miscarriage [25]. In addition, along with the presence of antibodies to eno-
lase-1, elevated serum levels of proinflammatory cytokines such as IL-1β, TNF-α, and 
PGE2 were detected, negatively affecting the development of pregnancy [85].
There are also studies on the relationship of antibodies to enolase-1 with the prema-
ture ovarian failure. When evaluating sera of 110 women with this diagnosis, antibodies 
to α-enolase-1 were detected in 21 of them (19.1 %) [31]. The authors suggested that the 
development of ovarian failure among patients with identified antibodies is based on de-
fects in systemic immunoregulation, which may appear before, during or after the onset 
of another autoimmune disease. The antibodies themselves, in this case, are considered an 
indicator of the autoimmune etiology of ovarian insufficiency and can be used as a diag-
nostic marker of the disease.
Despite the available data on the negative effect of antibodies to enolase-1  on the 
course of early pregnancy [25; 87], at present there are practically no studies evaluating the 
effectiveness of ART programs in the presence of the mentioned antibodies.
Antibodies to HCG
In a number of studies, antibodies to hCG are considered as a possible cause of mis-
carriage, infertility and IVF cycles failures [88–90].
In one of the studies, carriers of antibodies to hCG had a lower pregnancy rate and 
an increased frequency of spontaneous miscarriages after IVF treatment in comparison 
to negative control group. These frequency rates were comparable to those observed in 
women with antiphospholipid antibodies and antitrophoblast antibodies. Thus, the au-
thors pointed on the need to determine antibodies to hCG in patients undergoing IVF 
[90]. However, to date, there are no large studies and a sufficient evidence indicating a 
negative effect of antibodies to hCG on the effectiveness of ART programs.
Antibodies to aromatase
Aromatase is an enzyme complex that converts androgens into estrogens and consists 
of two components: aromatase of cytochrome p450 and flavoprotein nicotinamide ade-
nine nucleotide phosphate in reduced form (NADPH) cytochrome p450 reductase. In hu-
mans, aromatase p450 is found in many tissues and organs, such as: gonads, brain, adipose 
tissue, placenta, liver, skin, bones, blood vessels, endometrium, as well as in endometrioid 
heterotopies, in leiomyoma, in endometrial cancer and mammary gland cancer [91; 92]. 
Timely synthesis of aromatase in the ovarian follicle is responsible for cyclical changes in 
the level of estradiol in the blood. These changes modulate the structure and function of 
the female reproductive system and are also required for oocyte maturation, fertilization 
and implantation. Thus, the timely expression of aromatase in the ovary is critical for the 
autocrine regulation of folliculogenesis and endocrine control of the reproductive system.
Currently, there are studies evaluating the expression of this enzyme in certain gy-
necological diseases [93–97]. So, according to the results of Savina normogonadotropic 
anovulation in patients with external endometriosis and polycystic ovary syndrome is 
caused by aromatase deficiency in the ovaries and insufficient preovulatory rise in estra-
diol in the blood (p < 0.001) [93]. Foreign authors also report on the enzyme expression 
reduction seen in women with external endometriosis [94; 95].
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Yang et al. investigated the activity of aromatase in the follicular fluids of women 
diagnosed with polycystic ovaries during controlled ovarian stimulation in IVF cycles 
(n = 138). As a result, they found lower values of aromatase in follicular fluids of the study 
group [96]. The same data was reported by Russian scientists [97].
It is interesting to note that the aromatase activity of granulosa cells obtained from 
pregnant patients after IVF treatment, according to some authors, is significantly higher 
than in unpregnant patients after transferring the same number of embryos [98]. More- 
over, oocytes obtained from follicles with higher follicular fluid estradiol levels had a high-
er fertilization rate [99; 100]. The authors agree that the presence of aromatase in granu-
losa cells plays a fundamental role in follicular maturation, oocyte quality, and successful 
fertilization [101; 102].
At the same time, the nature of p450 ovarian aromatase deficiency is still not fully 
understood. Some authors point to a defect in the aromatase gene CYP19 among patients 
with polycystic ovary syndrome treated in IVF cycles [103]. According to other stud-
ies, aromatase deficiency may be associated with the hyperproduction of anti-Mülleri-
an hormone by granulosa cells, which, in turn, affects the promoter II of the aromatase 
p450 CYP19 gene, leading to a decrease in aromatase activity [104]. A number of domestic 
and foreign authors indicate that the incidence of autoimmune thyroiditis among women 
seeking help in infertility treatment clinics is significantly higher among patients with 
concomitant PCOS [4; 9; 105]. It is possible that in case of systemic autoimmune diseases, 
the immune response is also triggered directly to aromatase leading to the above tendency. 
This fact deserves the attention of the scientific community and requires further research.
Antibodies to Se-binding protein-1 (SBP-1)
The existence of autoimmune processes affecting ovarian tissue has long been known. 
Numerous researchers have identified the presence of antiovarian antibodies associated 
with premature ovarian failure [106–109] and infertility [110–112]. Antibodies to ovarian 
antigens comprise a heterogeneous group of autoantibodies directed against the cells of 
the ovaries. To date, the known antibodies are targeted to follicular cells, granulosa cells, 
stroma, theca (thecal antibodies) and some other components.
In 2010, a group of American and German scientists discovered a new target for an-
tiovarian antibodies, namely Se-binding protein-1, antibodies to which were detected in 
60 % of women with a history of infertility or premature ovarian failure [32]. By nature, 
SBP1  is a cytoplasmic protein found predominantly in epithelial cells, including those 
lining the surface of the ovary. It is known that depletion of selenium levels in follicular 
fluid is associated with idiopathic infertility [113]. In preclinical experimental studies of 
a contraceptive vaccine containing conjugated SBP1, also known as SP56, a 50 % decrease 
in the fertility of mice was observed [114].
In a recent study, Yu-Rice et al. found a significantly more frequent presence of anti-
SBP1 antibodies in the sera of women with ovulatory disorders (50.0 %, p = 0.007), idi-
opathic infertility (24.3 %, p = 0.02) and premature ovarian failure (28.0 %, p = 0.02) rel-
atively to the control group. Moreover, the same authors noted a more frequent occur-
rence of antibodies in serous ovarian tumors and suggested that anti-SBP-1 can be used 
as a predictor of ovarian cancer in the future [115]. This conclusion seems quite logical, 
given that in a number of experimental studies performed much earlier, the ability of 
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SBP1 to suppress tumor growth was noted [116; 117]. Thus, despite the currently lim-
ited information on the function and significance of Se-binding protein-1, it can be as-
sumed that autoantibodies to this protein can have a negative effect on female fertility 
and reproductive potential and, possibly, the effectiveness of infertility treatment within 
the framework of ART.
Antibodies to mesothelin
In the world literature, there are limited data on the effect of antibodies to mesothelin 
on the reproductive failure. It is known that the expression of this protein is increased 
in ovarian cancers [118], and mesothelin circulating in the blood has a relatively high 
specificity for ovarian cancer [119–121]. In addition, there is evidence of an increased in-
cidence of antibodies to mesothelin among women with verified ovarian cancer [122; 123] 
and a history of pelvic inflammatory disease [123]. In their study, Luborsky et al. carried 
out an assessment of mesothelin and antibodies to it in the serum of infertile women in 
order to identify the relationship between antibodies presence, infertility and the risk of 
ovarian cancer development in the future. According to the results obtained, antibodies 
to mesothelin were significantly more often detected in women with ovulatory dysfunc-
tion (59 %), premature ovarian failure (44 %), and infertility of unknown origin (25 %) in 
comparison to the control group. In the course of the study, the authors concluded that 
these autoantibodies are reliably determined in women with idiopathic infertility and may 
serve as a predictor of the development of ovarian carcinoma in the future for this group 
of patients [124]. Based on the revealed relationship between antibodies presence with 
infertility, it is relevant to perform a study on the role of this marker on the outcomes of 
ART programs, including embryological stages.
Conclusion
According to modern concepts, natural and autoimmune antibodies are produced 
in the human body. It is known that natural antibodies are involved in the formation of 
a normal immune response and provide homeostasis in organs and body systems. When 
the mechanisms of self-tolerance are violated, antibodies to own antigens are produced 
in compliance with the general laws of the humoral immune response. Autoantibodies 
can be involved in the pathogenesis of organ-specific and systemic autoimmune diseases, 
serve as harbingers of the disease, and be of great diagnostic value.
Autoimmune diseases are most widespread among women of reproductive age, which 
is due to the immunostimulatory effect of female sex hormones, the predominance of the 
Th2 response and the contribution of X chromosome genes to the immune response. The 
relationship between autoimmunity and reproduction is of great scientific and practical 
interest and has been actively studied for over four decades.
Based on the data presented in this review of the literature, autoimmunity can af-
fect all stages of the reproductive process, including oogenesis, implantation and preg-
nancy. In case of reproductive disorders, organ-specific (antiovarian, antitrophoblastic) 
and organ-specific (antiphospholipid, antinuclear, antithyroid and others) autoantibodies 
are determined. Autoantibodies are associated with polycystic ovary syndrome (PCOS), 
premature ovarian failure (POF), endometriosis, failure of in vitro fertilization cycles, and 
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may be responsible for early reproductive failure. It is also known about the combined 
course of autoimmune processes, an example of which is autoimmune polyglandular syn-
dromes of types 1 and 2. The combined course of autoimmune diseases or asymptomatic 
carriage of antibodies indicates the common mechanisms of development of various auto-
immune pathologies and allows us to make an assumption about “autoimmune reproduc-
tive failure syndrome”.
The abovementioned indicates the need to develop a line of reproductively sig-
nificant antibodies in application to direct, cross-over and cumulative assessment of the 
role of autoimmune antibodies carriage in the implementation of reproductive failures, 
bearing in mind new approaches to the strategy of overcoming autoimmune reproduc-
tive failure. 
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